Ethamolin
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Ethamolin
- Generic name
- ETHANOLAMINE OLEATE
- Manufacturer
- QOL Medical, LLC.
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- a9c1d8c5-443e-400e-a42c-16a25fb47231
- SPL ID
- 45a0d13c-0c73-6c2c-e063-6394a90aaa54
- Version
- 14
- Effective date
- 2025-12-10
- Source export date
- 2026-09-28
- Source partition
- 10
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0010-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/4bbc9760f647649b787710953d978bd6419e899ba8b90f32c3d972aae43947f8/drug-label-0010-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 06:08:47
| Harmonized routes |
|---|
| INTRAVENOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | NDA | 019357 | derived:openfda.application_number |
| application number | NDA019357 | openfda.application_number | |
| brand name | Ethamolin | openfda.brand_name | |
| generic name | ETHANOLAMINE OLEATE | openfda.generic_name | |
| manufacturer name | QOL Medical, LLC. | openfda.manufacturer_name | |
| ndc | package | 67871-479-06 | openfda.package_ndc |
| ndc | product | 67871-479 | openfda.product_ndc |
| ndc11 | package | 67871047906 | derived:openfda.package_ndc |
| rxcui | 106675 | openfda.rxcui | |
| rxcui | 205745 | openfda.rxcui | |
| spl id | 45a0d13c-0c73-6c2c-e063-6394a90aaa54 | id | |
| spl set id | a9c1d8c5-443e-400e-a42c-16a25fb47231 | set_id | |
| unii | U4RY8MRX7C | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNINGS ETHAMOLlN Injection should be used in pregnant women only when clearly needed (see PRECAUTIONS). The practice of injecting varicosities of the leg with ETHAMOLlN Injection is not supported by adequately controlled clinical trials. Therefore, such use is not recommended.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS The reported frequency of complications/adverse events per injection session was 13%. The most common complications were pleural effusion/infiltration (2.1%), esophageal ulcer (2.1 %), pyrexia (1.8%), retrosternal pain (1.6%), esophageal stricture (1.3%), and pneumonia (1.2%). Other adverse local esophageal reactions have also been reported at rates of 0.1 to 0.4%, including esophagitis, tearing of the esophagus, sloughing of the mucosa overlying the injected varix, ulceration, stricture, necrosis, periesophageal abscess and perforation (see PRECAUTIONS). These complications appear to be dependent upon the dose and the patient's clinical state. Bacteremia has been observed in patients following injection of esophageal varices with ETHAMOLlN. Pyrexia and retrosternal pain are not infrequently observed during the post-injection period. Fatal aspiration pneumonia has occurred in patients with esophageal varices who underwent ETHAMOLIN Injection Sclerotherapy (see PRECAUTIONS). Anaphylactic shock and acute renal failure with spontaneous recovery have occurred (see PRECAUTIONS). A case of disseminated intravascular coagulation has been reported. Spinal cord paralysis due to occlusion of the anterior spinal artery has been reported in one child eight hours after ETHAMOLIN sclerotherapy.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.